Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

CYT Cyteir Therapeutics Inc

0.00 (0.00%)
Last Updated: 20:00:00
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 3.04
Ask Price 3.14
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Cyteir Therapeutics Inc CYT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 3.02 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 1.67 - 3.19
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 3.02 USD

Cyteir Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 108.71M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cyteir Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CYT Message Board. Create One! See More Posts on CYT Message Board See More Message Board Posts

Historical CYT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months3.103.152.993.04472,994-0.08-2.58%
6 Months3.043.192.993.07134,577-0.02-0.66%
1 Year2.293.191.672.82188,6310.7331.88%
3 Years16.5023.101.135.53135,353-13.48-81.70%
5 Years16.5023.101.135.53135,353-13.48-81.70%

Cyteir Therapeutics Description

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing the next generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Its lead program is CYT-0851, which is designed to exploit a novel synthetic lethality between overexpression of a family of DNA damaging enzymes called cytidine deaminases and functional inhibition of homologous recombination, a DNA repair pathway critical for the survival of some cancers. Its Pre-clinical program is CYT-1853, which is designed to exploit the same novel synthetic lethality targeted by CYT-085.

Your Recent History

Delayed Upgrade Clock